Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D.

PLoS One. 2017 Feb 9;12(2):e0171871. doi: 10.1371/journal.pone.0171871. eCollection 2017.

2.

Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.

Tonry C, Armstrong J, Pennington SR.

Oncotarget. 2017 Feb 28;8(9):14374-14394. doi: 10.18632/oncotarget.14605.

3.

Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.

Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner BC, Oktem G.

PLoS One. 2015 Oct 20;10(10):e0141090. doi: 10.1371/journal.pone.0141090. eCollection 2015.

4.

Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine.

Kim HS, Sung YJ, Paik S.

Yonsei Med J. 2015 Sep;56(5):1186-98. doi: 10.3349/ymj.2015.56.5.1186. Review.

5.

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.

Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, Pullambhatla M, Shen CJ, Foss CA, Pomper MG.

J Nucl Med. 2015 Sep;56(9):1401-1407. doi: 10.2967/jnumed.115.155929. Epub 2015 Jul 16.

6.

In vitro and in vivo model systems used in prostate cancer research.

Cunningham D, You Z.

J Biol Methods. 2015;2(1). pii: e17.

7.

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.

Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3.

8.

Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences.

Chang KH, Ercole CE, Sharifi N.

Br J Cancer. 2014 Sep 23;111(7):1249-54. doi: 10.1038/bjc.2014.268. Epub 2014 May 27. Review.

9.

Comprehensive functional annotation of 77 prostate cancer risk loci.

Hazelett DJ, Rhie SK, Gaddis M, Yan C, Lakeland DL, Coetzee SG; Ellipse/GAME-ON consortium; Practical consortium, Henderson BE, Noushmehr H, Cozen W, Kote-Jarai Z, Eeles RA, Easton DF, Haiman CA, Lu W, Farnham PJ, Coetzee GA.

PLoS Genet. 2014 Jan 30;10(1):e1004102. doi: 10.1371/journal.pgen.1004102. eCollection 2014 Jan.

10.

CoMAGC: a corpus with multi-faceted annotations of gene-cancer relations.

Lee HJ, Shim SH, Song MR, Lee H, Park JC.

BMC Bioinformatics. 2013 Nov 14;14:323. doi: 10.1186/1471-2105-14-323.

11.

Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer.

Long MD, Thorne JL, Russell J, Battaglia S, Singh PK, Sucheston-Campbell LE, Campbell MJ.

Carcinogenesis. 2014 Feb;35(2):262-71. doi: 10.1093/carcin/bgt334. Epub 2013 Oct 8.

12.

Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.

Mazzoleni S, Jachetti E, Morosini S, Grioni M, Piras IS, Pala M, Bulfone A, Freschi M, Bellone M, Galli R.

Stem Cells Transl Med. 2013 Sep;2(9):678-89. doi: 10.5966/sctm.2013-0041. Epub 2013 Jul 24.

13.

The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.

Chhipa RR, Halim D, Cheng J, Zhang HY, Mohler JL, Ip C, Wu Y.

Prostate. 2013 Oct;73(14):1483-94. doi: 10.1002/pros.22696. Epub 2013 Jun 28.

14.

Induced pluripotency of human prostatic epithelial cells.

Zhao H, Sun N, Young SR, Nolley R, Santos J, Wu JC, Peehl DM.

PLoS One. 2013 May 22;8(5):e64503. doi: 10.1371/journal.pone.0064503. Print 2013.

15.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

16.

Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer.

Sterenczak KA, Meier M, Glage S, Meyer M, Willenbrock S, Wefstaedt P, Dorsch M, Bullerdiek J, Murua Escobar H, Hedrich H, Nolte I.

BMC Cancer. 2012 Jul 11;12:284.

17.

Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line.

Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross ME, Kuhn P.

Phys Biol. 2012 Feb;9(1):016002. doi: 10.1088/1478-3975/9/1/016002. Epub 2012 Feb 3.

18.

Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.

Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA.

Prostate. 2012 Sep 15;72(13):1412-22. doi: 10.1002/pros.22489. Epub 2012 Jan 31.

19.

Mouse models of prostate cancer.

Valkenburg KC, Williams BO.

Prostate Cancer. 2011;2011:895238. doi: 10.1155/2011/895238. Epub 2011 Feb 23.

20.

Supplemental Content

Support Center